BEAM Beam Therapeutics Inc. Insider Trading

CEO Evans sold 30,078 shares at $24.58 on 2026-04-01; stock down 31.6% from 52-week high and trading 0.6% below sale price.

CEO John M. Evans sold 30,078 shares (30.1K shares) of BEAM at $24.58 on 2026-04-01 for $739,317.24, reducing his holdings by 2.8% to 1,047,205 shares. The stock is currently at $24.23—a slight 0.6% discount to the sale price—and down 31.6% from its 52-week high of $35.41. At the same ticker, his cross-ticker track record shows a 70.00% well-timed rate on prior sells, but at BEAM specifically, outcomes on his prior 5 trades remain inconclusive: the most recent BEAM sales (2026-03-31 and 2026-03-30) have no measurable outcomes yet, earlier January 2026 sales showed mixed 30-day returns (ranging from -2.5% to +0.7%), and 0 of 0 prior BEAM sales were well-timed at the 90-day mark. Fundamentally, BEAM is an unprofitable biotech company with $9.7M in latest quarterly revenue, a $-112.7M net loss, yet 120.0% annual revenue growth; the $2.5B market cap reflects deep pre-commercial positioning. This sale occurs in the context of recent price weakness and multiple consecutive sales by the same insider within days.

BEAM CEO Evans sells 50,000 shares in 2 transactions for $1,128,315.00; stock down -15.6% (30d), -12.6% (90d)

CEO John M. Evans sold 50,000 shares (4.4% of pre-transaction holdings) across two separate transactions on 2026-03-30 and 2026-03-31 at a blended average price of $22.57, raising $1,128,315.00. The stock has declined -15.6% in the 30 days and -12.6% in the 90 days since these sales, with current price at $24.22 still -31.6% from the 52-week high of $35.41. Evans' cross-ticker track record shows a 70.00% well-timed rate on 15 prior sells (average 90d return -9.6%), indicating a demonstrated pattern of selling before declines. His prior trades at BEAM specifically show mixed recent outcomes (5 prior trades from late January through early April 2026), though measurable 90-day results are not yet available for most. The company remains unprofitable with net income of $-112,728,000.00 against quarterly revenue of $9,698,000.00, though annual revenue growth stands at +120.0% year-over-year.

BEAM President Ciaramella sells 35,000 shares ($1.1M) at $32.00; stock now $28.92, down 18.3% from 52-week high

Ciaramella Giuseppe, President of Beam Therapeutics, sold 35,000 shares (35.0K shares) at $32.00 on 2026-02-24, reducing his stake by 15.5% to 190,216 shares (190.2K shares). The sale occurred near the stock's 52-week high of $35.41; the stock has since fallen to $28.92, now 18.3% below that peak. At his cross-ticker track record level, his prior 4 open-market sells showed a 75.00% well-timed rate with an average 90-day return of -22.3%, while at this specific ticker, 3 of 4 prior BEAM sales showed negative 90-day outcomes. The company remains unprofitable with net income of $-112.7M over its last full fiscal year, though revenue surged 120.0% year-over-year. The timing of this sale—executed at a high point relative to current levels and consistent with his historical pattern of selling before subsequent declines—warrants close observation of the company's profitability trajectory and market momentum.

CEO Evans sells 50,000 shares for $1.4M at $28.87 avg; stock down -21.2% from 52-week high

John M. Evans, CEO of Beam Therapeutics, executed 4 separate sales totaling 50,000 shares for $1,443,528.45 across January 29–30, 2026, at a blended average price of $28.87. The sales reduced his holdings from 1,036,667 shares to 986,667 shares (-4.8%). The current stock price of $27.92 sits -21.2% from the 52-week high of $35.41, indicating the stock has declined materially since his transaction prices. Beam's fundamentals show severe deterioration: annual revenue contracted -83.2% year-over-year to $9,698,000.00 in the latest quarter, net income was $-112,728,000.00, and the company remains unprofitable. Evans' prior 5 trades at BEAM show mixed timing: 3 of 5 prior sales were well-timed at the 90-day mark, though his cross-ticker track record across 10 prior sales shows a 90d well-timed rate of 70.00% with an average 90-day return of -9.6%—indicating better timing discipline historically. The combination of large shareholder reduction amid deteriorating revenue trends and current price weakness warrants investor scrutiny of the company's operational trajectory.

CLO Christine Bellon sells 18,629 shares at $34.61 avg; holds 97,038 shares post-sale in unprofitable BEAM

Christine Bellon, Chief Legal Officer of Beam Therapeutics, executed 3 separate sales totaling 18,629 shares for $644,831.51 at a blended average price of $34.61 on 2026-01-15, reducing her holdings by 16.1% to 97,038 shares. The sales were priced near the 52-week high of $35.41, occurring while the stock has risen 16.5% over 30 days and 11.8% over 90 days. Beam Therapeutics remains unprofitable with a net income of $-112,728,000.00 for the latest fiscal year and revenue that declined 83.2% annually, characteristics that typically warrant executive scrutiny. The volume and timing of this multi-transaction sale merit monitoring given the company's financial deterioration and the insider's legal responsibilities as CLO.

CEO Evans sells 50,000 BEAM shares for $1,228,322.50; prior trades at this ticker 4-of-5 well-timed at 90d; stock +37.3% in 30d but fundamentals deteriorating.

John M. Evans (CEO) executed 2 separate sales totaling 50,000 shares for $1,228,322.50 on October 1–2, 2025, at an average price of $24.57, reducing holdings by 4.8% to 986,667 shares. His timing record at BEAM is notably strong: 4 of 5 prior sales at this ticker were well-timed at the 90-day mark, suggesting pattern-based predictive value. However, context complicates the signal: BEAM's stock has surged +37.3% over the prior 30 days and stands only -24.5% below its 52-week high, yet the company posted $-102,291,000.00 net income in the latest full fiscal year, annual revenue collapsed -83.2%, and quarterly revenue stood at only $8,466,000.00. The sale occurs during a sharp rally in a fundamentally deteriorating business, which may reflect opportunistic liquidity-raising rather than forward-looking concern. Given strong prior sell-timing at this ticker but elevated price relative to business trajectory, this warrants monitoring of whether the 90-day pattern holds.

CEO Evans sells 30,663 BEAM shares at $18.35; stock now at $16.46, down 51.7% from 52-week high of $34.09

John M. Evans, CEO, sold 30,663 shares of Beam Therapeutics at $18.35 on 2025-04-01, reducing his holdings from 1,016,912 shares to 986,249 shares. The sale occurred at a price significantly above the current market price of $16.46, which stands 51.7% below the 52-week high of $34.09 and represents a 37.8% decline over the prior 30 days. Beam's fundamentals show acute deterioration: revenue contracted 83.2% year-over-year to $14,269,000.00, the company posted a net loss of $96,668,000.00 in the latest quarter, and remains unprofitable on a full-year basis, with a market cap of only $1,377,509,335.70. At his same-ticker prior trades at BEAM, Evans achieved well-timed outcomes on 2 of 3 measurable 90-day periods, with mixed near-term results on his two January 2025 sales; this April sale must be interpreted alongside the severe operational contraction and steep price deterioration already underway in the stock.

Chief Medical Officer Simon Amy sold 30.6K shares ($547.8K) at $17.92 average; stock down 51.7% from 52-week high, revenue collapsed 83.2% YoY.

Simon Amy, Chief Medical Officer at Beam Therapeutics, executed 2 separate sales totaling 30,563 shares for $547,835.45 on April 1–2, 2025, reducing his holdings by 31.7%. The sales occurred at a blended average price of $17.92, while the stock now trades at $16.46—51.7% below its 52-week high and 37.8% lower over the past 30 days. The company is unprofitable with net income of $-96,668,000.00 for its most recent full fiscal year, and quarterly revenue of $14,269,000.00 represents an 83.2% annual revenue decline. Critically, his prior 2 sales at BEAM were both well-timed at the 90-day mark (prior-year sales showed 90d returns of -24.5% and -27.1%), and his cross-ticker track record shows a 100.00% well-timed rate across all prior sales, with an average 90d return of -25.8%. The sale pattern—discretionary, material reduction of 31.7% of pre-transaction holdings, and execution amid deteriorating fundamentals and severe downward price momentum—warrants investor scrutiny of forward guidance and operational developments at Beam.

CEO Evans sells 30,000 BEAM shares for $802.5K; stock down 43.2% from 52-week high despite +520.0% revenue growth

Evans John M., CEO of Beam Therapeutics, executed 2 separate sales totaling 30,000 shares for $802,483.82, reducing his holdings from 938.7K to 908.7K shares (-3.2%). His same-ticker selling history at BEAM shows mixed timing—4 of 5 prior sells had negative 90-day returns (well-timed exits before declines), yet this transaction follows a context where the stock is currently down 43.2% from its 52-week high of $45.07, despite the company reporting annual revenue growth of +520.0%. The company remains unprofitable (latest net income: $-96.7M against quarterly revenue of $14.3M), creating a valuation disconnect: exceptional topline growth has not translated to profitability or stock appreciation. Evans' prior transactions at this ticker show he has historically sold near local peaks before subsequent declines, suggesting pattern recognition or informed positioning, though his cross-ticker well-timed rate of 80.00% is weaker at the single-ticker level.

BEAM President sold 51,110 shares ($1.3M) on 2024-11-06 at $26.36; stock now -40.0% from 52-week high. Prior trades well-timed.

Ciaramella Giuseppe, President, disposed of 51,110 shares (31.9% of pre-transaction holdings) at $26.36, reducing his position from 160,260 to 109,150 shares. His cross-ticker track record shows a 100.00% well-timed rate at the 90-day mark across prior sells, with an average 90d return of -43.7%, and his two prior measured sales at BEAM in July 2023 were similarly well-timed, posting 90-day returns of -44.7% and -42.7%. The current stock price of $27.06 sits -40.0% below the 52-week high of $45.07, indicating significant downside has already occurred since the transaction. The company reported revenue of $14,269,000.00 in its latest quarter with a net loss of $-96,668,000.00 and remains unprofitable on a full-year basis, though annual revenue growth stands at +520.0%. The pattern of consistent well-timed exits at this ticker, paired with deteriorating financial returns (large quarterly losses despite revenue growth), aligns with the observed post-transaction decline.